Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer Inc.    PFE

PFIZER INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer : COBALT advised Pfizer's Upjohn spin-off on merger with Mylan NV

11/30/2020 | 09:49am EST

COBALT provided Latvian law advice to Pfizer's off-patented branded and generic medicines business Upjohn on merger transaction with Mylan NV and formation of a new joint venture Viatris Inc.

The transaction was announced in 2019 and it was closed on 16 November 2020.

Newly established healthcare company Viatris Inc. employs approximately 45 000 employees and its global portfolio comprises more than 1 400 medicines.

Contact:

Tel: +372 665 1888

(C) 2020 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
PFIZER INC. -0.57% 36.51 Delayed Quote.-0.22%
VIATRIS INC. 1.32% 17.6818 Delayed Quote.-6.94%
All news about PFIZER INC.
03:58pPFIZER : States report vaccine shortages and cancel appointments
AQ
03:38pWHO plans slew of COVID-19 vaccine approvals for global rollout
RE
02:35pPFIZER : Delay in Pfizer vaccine shipments frustrate Europe, Canada
AQ
01:59pGerman COVID-19 fight hit by delay to Pfizer vaccine
RE
12:02pPFIZER : and BioNTech PuResults of Study Showing COVID-19 Vaccine Elicits Antibo..
PU
11:56aThree COVID-19 vaccines under final review for emergency use - WHO
RE
10:26aWHO plans slew of COVID-19 vaccine approvals for global rollout - document
RE
09:18aUPDATE1 : Japan secures extra Pfizer vaccine doses as Feb. 15 approval expected
AQ
08:48aChinese media criticise Pfizer COVID-19 vaccine, tout local shots
RE
08:17aPFIZER : BioNTech Say Study Results Show COVID Vaccine Elicits Antibodies that N..
MT
More news
Financials (USD)
Sales 2020 48 425 M - -
Net income 2020 19 798 M - -
Net Debt 2020 43 571 M - -
P/E ratio 2020 11,9x
Yield 2020 3,92%
Capitalization 204 B 204 B -
EV / Sales 2020 5,12x
EV / Sales 2021 4,44x
Nbr of Employees 88 300
Free-Float 59,1%
Chart PFIZER INC.
Duration : Period :
Pfizer Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 41,94 $
Last Close Price 36,73 $
Spread / Highest target 44,3%
Spread / Average Target 14,2%
Spread / Lowest Target -1,99%
EPS Revisions
Managers and Directors
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Suzanne Nora Johnson Independent Director
Helen H. Hobbs Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC.-0.22%204 160
JOHNSON & JOHNSON3.43%428 525
ROCHE HOLDING AG2.98%307 190
NOVARTIS AG2.24%218 823
MERCK & CO., INC.1.70%210 474
ABBVIE INC.4.69%198 051